Eli Lilly (LLY) Invested Capital (2009 - 2026)

Eli Lilly has reported Invested Capital for 18 years, with the latest figure at $72.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 1685.02% year-over-year to $72.8 billion; the trailing twelve-month figure through Mar 2026 stood at $72.8 billion (up 1685.02% YoY), and the FY2025 full-year result was $69.0 billion, up 160.57% from the prior year.
• Invested Capital for Q1 2026 stood at $72.8 billion, up from $69.0 billion in the prior quarter.
• The five-year high for Invested Capital was $72.8 billion in Q1 2026, with the low at -$4.3 billion in Q1 2024.
• Historically, Invested Capital has averaged $20.2 billion across 5 years, with a median of $14.9 billion in 2022.
• Annual changes were most pronounced in 2024 — Invested Capital tumbled 4086.0% — and 2025, when it jumped 3489.19%.
• Eli Lilly's Invested Capital stood at $14.9 billion in 2022, then advanced by 7.95% to $16.1 billion in 2023, then soared by 64.65% to $26.5 billion in 2024, then soared by 160.57% to $69.0 billion in 2025, then grew by 5.44% to $72.8 billion in 2026.
• The last three Invested Capital figures came in at $72.8 billion (Q1 2026), $69.0 billion (Q4 2025), and $63.8 billion (Q3 2025), per Business Quant data.